Cargando…

Dosimetry and optimal scan time of [(18)F]SiTATE-PET/CT in patients with neuroendocrine tumours

PURPOSE: Radiolabelled somatostatin analogues targeting somatostatin receptors (SSR) are well established for combined positron emission tomography/computer tomography (PET/CT) imaging of neuroendocrine tumours (NET). [(18)F]SiTATE has recently been introduced showing high image quality, promising c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Beyer, Leonie, Gosewisch, Astrid, Lindner, Simon, Völter, Friederike, Mittlmeier, Lena M., Tiling, Reinhold, Brendel, Matthias, Cyran, Clemens C., Unterrainer, Marcus, Rübenthaler, Johannes, Auernhammer, Christoph J., Spitzweg, Christine, Böning, Guido, Gildehaus, F. J., Jurkschat, Klaus, Wängler, Carmen, Wängler, Björn, Schirrmacher, Ralf, Wenter, Vera, Todica, Andrei, Bartenstein, Peter, Ilhan, Harun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8440281/ https://www.ncbi.nlm.nih.gov/pubmed/33928401 http://dx.doi.org/10.1007/s00259-021-05351-x

Ejemplares similares

Comparison of somatostatin receptor expression in patients with neuroendocrine tumours with and without somatostatin analogue treatment imaged with [(18)F]SiTATE
por: Eschbach, Ralf S., et al.
Publicado: (2023)

Favorable SSTR subtype selectivity of SiTATE: new momentum for clinical [(18)F]SiTATE PET
por: Wängler, Carmen, et al.
Publicado: (2022)

Next-generation PET/CT imaging in meningioma—first clinical experiences using the novel SSTR-targeting peptide [(18)F]SiTATE
por: Unterrainer, Marcus, et al.
Publicado: (2023)

Correction to: Next‑generation PET/CT imaging in meningioma—first clinical experiences using the novel SSTR‑targeting peptide [(18)F]SiTATE
por: Unterrainer, Marcus, et al.
Publicado: (2023)

Salvage PRRT with (177)Lu-DOTA-octreotate in extensively pretreated patients with metastatic neuroendocrine tumor (NET): dosimetry, toxicity, efficacy, and survival
por: Rudisile, S., et al.
Publicado: (2019)

Correlation of an Index-Lesion-Based SPECT Dosimetry Method with Mean Tumor Dose and Clinical Outcome after (177)Lu-PSMA-617 Radioligand Therapy
por: Völter, Friederike, et al.
Publicado: (2021)

Response to (225)Ac-PSMA-I&T after failure of long-term (177)Lu-PSMA RLT in mCRPC
por: Ilhan, Harun, et al.
Publicado: (2020)

Toxicity of a combined therapy using the mTOR-inhibitor everolimus and PRRT with [(177)Lu]Lu-DOTA-TATE in Lewis rats
por: Zellmer, Johannes, et al.
Publicado: (2020)

Effects of the Minimal Extrathyroidal Extension on Early Response Rates after (Adjuvant) Initial Radioactive Iodine Therapy in PTC Patients
por: Ahmaddy, Freba, et al.
Publicado: (2020)

Molecular Imaging with (18)F-FDG PET/CT and (99m)Tc-MIBI SPECT/CT in Osteitis Fibrosa Cystica Generalisata
por: Holzgreve, Adrien, et al.
Publicado: (2021)

The diagnostic challenge of coexistent sarcoidosis and thyroid cancer – a retrospective study
por: Wenter, Vera, et al.
Publicado: (2021)

Evaluation of the Efficacy of a Combined Treatment Using the mTOR-Inhibitor Everolimus and [177Lu]Lu-DOTA-TATE in Nude CD1 Mice with SSTR-Expressing Pancreatic AR42J Xenograft Tumors
por: Zellmer, Johannes, et al.
Publicado: (2022)

Image-based dosimetry for (225)Ac-PSMA-I&T therapy using quantitative SPECT
por: Gosewisch, A., et al.
Publicado: (2020)

Patient-specific image-based bone marrow dosimetry in Lu-177-[DOTA(0),Tyr(3)]-Octreotate and Lu-177-DKFZ-PSMA-617 therapy: investigation of a new hybrid image approach
por: Gosewisch, Astrid, et al.
Publicado: (2018)

Influence of dosimetry method on bone lesion absorbed dose estimates in PSMA therapy: application to mCRPC patients receiving Lu-177-PSMA-I&T
por: Brosch-Lenz, Julia, et al.
Publicado: (2021)

Good practices for the automated production of (18)F-SiFA radiopharmaceuticals
por: Blok, Simon, et al.
Publicado: (2023)

Correction to: Influence of dosimetry method on bone lesion absorbed dose estimates in PSMA therapy: application to mCRPC patients receiving Lu-177-PSMA-I&T
por: Brosch-Lenz, Julia, et al.
Publicado: (2021)

Clinical impact of follicular oncocytic (Hürthle cell) carcinoma in comparison with corresponding classical follicular thyroid carcinoma
por: Wenter, Vera, et al.
Publicado: (2020)

3D Monte Carlo bone marrow dosimetry for Lu-177-PSMA therapy with guidance of non-invasive 3D localization of active bone marrow via Tc-99m-anti-granulocyte antibody SPECT/CT
por: Gosewisch, Astrid, et al.
Publicado: (2019)

(18)F-Labeled Silicon-Based Fluoride Acceptors: Potential Opportunities for Novel Positron Emitting Radiopharmaceuticals
por: Bernard-Gauthier, Vadim, et al.
Publicado: (2014)

Nephroprotective effects of enalapril after [177Lu]-DOTATATE therapy using serial renal scintigraphies in a murine model of radiation-induced nephropathy
por: Ilhan, Harun, et al.
Publicado: (2016)

(68)Ga-EMP-100 PET/CT—a novel ligand for visualizing c-MET expression in metastatic renal cell carcinoma—first in-human biodistribution and imaging results
por: Mittlmeier, Lena M., et al.
Publicado: (2021)

Cost-Effectiveness Analysis of (68)Ga DOTA-TATE PET/CT, (111)In-Pentetreotide SPECT/CT and CT for Diagnostic Workup of Neuroendocrine Tumors
por: Froelich, Matthias Frank, et al.
Publicado: (2021)

t-Bu(2)SiF-Derivatized D(2)-Receptor Ligands: The First SiFA-Containing Small Molecule Radiotracers for Target-Specific PET-Imaging
por: Iovkova-Berends, Ljuba, et al.
Publicado: (2011)

Total Tumor Volume on (18)F-PSMA-1007 PET as Additional Imaging Biomarker in mCRPC Patients Undergoing PSMA-Targeted Alpha Therapy with (225)Ac-PSMA-I&T
por: Unterrainer, Lena M., et al.
Publicado: (2022)

Feasibility of Different Tumor Delineation Approaches for (18)F-PSMA-1007 PET/CT Imaging in Prostate Cancer Patients
por: Mittlmeier, Lena M., et al.
Publicado: (2021)

Quantitative myocardial perfusion SPECT/CT for the assessment of myocardial tracer uptake in patients with three-vessel coronary artery disease: Initial experiences and results
por: Lehner, Sebastian, et al.
Publicado: (2021)

(18)F-FDG-PET/CT in Patients with Advanced, Radioiodine Refractory Thyroid Cancer Treated with Lenvatinib
por: Ahmaddy, Freba, et al.
Publicado: (2021)

Course of Disease and Clinical Management of Patients with Poorly Differentiated Thyroid Carcinoma
por: Grawe, Freba, et al.
Publicado: (2021)

Recent Advances in the Clinical Translation of Silicon Fluoride Acceptor (SiFA) (18)F-Radiopharmaceuticals
por: Gower-Fry, Lexi, et al.
Publicado: (2021)

Feasibility of [(68)Ga]Ga-FAPI-46 PET/CT for detection of nodal and hematogenous spread in high-grade urothelial carcinoma
por: Unterrainer, Lena M., et al.
Publicado: (2022)

Biodistribution and dosimetry for combined [(177)Lu]Lu-PSMA-I&T/[(225)Ac]Ac-PSMA-I&T therapy using multi-isotope quantitative SPECT imaging
por: Delker, Astrid, et al.
Publicado: (2023)

Investigation of image-based lesion and kidney dosimetry protocols for (177)Lu-PSMA-I&T therapy with and without a late SPECT/CT acquisition
por: Resch, Sandra, et al.
Publicado: (2023)

(18)F-PSMA-1007 PET/CT for response assessment in patients with metastatic renal cell carcinoma undergoing tyrosine kinase or checkpoint inhibitor therapy: preliminary results
por: Mittlmeier, L. M., et al.
Publicado: (2020)

Bimodal Imaging Probes for Combined PET and OI: Recent Developments and Future Directions for Hybrid Agent Development
por: Seibold, Uwe, et al.
Publicado: (2014)

Identification of a Suitable Peptidic Molecular Platform for the Development of NPY(Y(1))R‐Specific Imaging Agents
por: Krieger, Korbinian, et al.
Publicado: (2020)

Preliminary experience with dosimetry, response and patient reported outcome after (177)Lu-PSMA-617 therapy for metastatic castration-resistant prostate cancer
por: Fendler, Wolfgang P., et al.
Publicado: (2016)

Toward Single-Time-Point Image-Based Dosimetry of (177)Lu-PSMA-617 Therapy
por: Brosch-Lenz, Julia, et al.
Publicado: (2023)

Initial Evaluation of Therapy Response after Adjuvant Radioiodine Therapy in Patients with Early-Stage Papillary Thyroid Cancer—Does Time Matter?
por: Grawe, Freba, et al.
Publicado: (2022)

Molecular imaging of cardiac CXCR4 expression in a mouse model of acute myocardial infarction using a novel (68)Ga-mCXCL12 PET tracer
por: Zacherl, Mathias Johannes, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_v2n0v14558gqsjjdq7o9gfm8rm